Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

199 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

Vital Signs Screening Visit Mepolizumab HES NCT00086658 - Vital Signs Screening Visit

- 4/6/17 - 1 formulario, 1 itemgroup, 9 items, 1 idioma
Itemgroup: VITAL SIGNS
Study part: Vital Signs Screening Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

12-Lead ECG Screening Visit Mepolizumab HES NCT00086658 - 12-Lead ECG Screening Visit

- 4/6/17 - 1 formulario, 1 itemgroup, 3 items, 1 idioma
Itemgroup: 12-Lead ECG
Study part: 12-Lead ECG Screening Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

HES History or Prior HES Therapies Screening Visit Mepolizumab HES NCT00086658 - HES History or Prior HES Therapies Screening Visit

- 4/6/17 - 1 formulario, 2 itemgroups, 27 items, 1 idioma
Itemgroups: DIAGNOSIS, Therapy HES
Study part: HES History or Prior HES Therapies Screening Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

HES Related Medical Conditions Screening Visit Mepolizumab HES NCT00086658 - HES Related Medical Conditions Screening Visit

- 4/6/17 - 1 formulario, 8 itemgroups, 34 items, 1 idioma
Itemgroups: Cardiac disorders, NERVOUS SYSTEM DISORDERS, Skin diseases, GASTROINTESTINAL DISORDERS, MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS, EYE DISORDERS, RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS, medical history Hypereosinophilic Syndrome
Study part: HES Related Medical Conditions Screening Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Medical Conditions Screening Visit Mepolizumab HES NCT00086658 - Medical Conditions Screening Visit

- 4/6/17 - 1 formulario, 1 itemgroup, 23 items, 1 idioma
Itemgroup: MEDICAL CONDITIONS
Study part: Medical Conditions Screening Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Demographics Screening Visit Mepolizumab HES NCT00086658 - Demographics Screening Visit

- 4/6/17 - 1 formulario, 1 itemgroup, 6 items, 1 idioma
Itemgroup: Demography
Study part: Demographics Screening Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Eligibility Criteria Worksheet Screening Visit Mepolizumab HES NCT00086658 - Eligibility Criteria Worksheet Screening Visit

- 4/6/17 - 1 formulario, 2 itemgroups, 12 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study part: Eligibility Criteria Worksheet Screening Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial